MedPacto, Inc (235980) Fair Value & Analysis
Healthcare · KR · Market cap 89.5B KRW
Fair value as of: Jul 22, 2026
From 1 valuation models · updated 19 days ago
Share price +5.3% over the past month.
Below-average quality, and screening another 58% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,542 KRW). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (814.25 KRW to 1,542 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 2,240 KRW – 82,991 KRW · fair‑value band 814.25 KRW – 1,542 KRW · the 2,960 KRW price screens above the 1,234 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
MedPacto, Inc (235980) currently trades at 2,960 KRW, while our model-based Fair Value estimate is 1,234 KRW, implying the stock looks roughly 58.3% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 4.8B KRW. Revenue grew 206.2% year over year. It earns a return on equity of -27.2%. Net debt stands at 59.9B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 814.25 KRW (bear case) to 1,542 KRW (bull case); at 2,960 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -58%, 235980 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 235980 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MedPacto, Inc. engages in the development and sale of marker-based new drugs in South Korea. MedPacto, Inc. was established in 2013 and is based in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MedPacto, Inc reported revenue of 3.9B KRW in FY2025 versus 0 KRW in FY2021. Reported net income was −12.8B KRW in FY2025.
235980 screens 58% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 604 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| RemeGen Co 688331 | ¥134.45 | ¥23.19 | -83% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare MedPacto, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MedPacto, Inc (235980) overvalued or undervalued?
What is the fair value of 235980?
What is the quality score of 235980?
What is the revenue of MedPacto, Inc (235980)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MedPacto, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.